Thelma Witteveen
Papers
2
Total Citations
48
H-Index
2
About
Dr. Thelma Witteveen is a distinguished researcher in urologic oncology, with a specialized focus on advanced prostate cancer imaging and treatment response evaluation. Her work centers on the critical intersection of multi-parametric magnetic resonance imaging (mpMRI) and prostate-specific membrane antigen (PSMA) PET/CT in guiding clinical decision-making for prostate cancer patients. Dr. Witteveen’s most influential contribution is her seminal 2017 study on seminal vesicle invasion detected by mpMRI, which correlated imaging findings with histopathology—a work that has garnered 43 citations and established foundational criteria for preoperative staging. She further advanced the field by investigating PSMA PET/CT’s role in assessing initial treatment response among patients undergoing salvage radiation therapy after radical prostatectomy for biochemical recurrence, demonstrating how this imaging modality can identify candidates with no detectable metastases and predict short-term oncologic outcomes. Her research directly impacts clinical protocols by refining patient selection for salvage therapies and improving prognostic accuracy. Dr. Witteveen’s work bridges radiology and oncology, providing urologists and radiation oncologists with evidence-based imaging biomarkers to personalize treatment for recurrent prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1
- 2